ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan

Core Viewpoint - Oryzon Genomics has received a "Decision to grant" communication from the Japanese Patent Office for its patent application related to vafidemstat, an LSD1 inhibitor in clinical development for treating psychiatric disorders, specifically targeting aggression and social withdrawal [1][2][3] Patent and Intellectual Property - The allowed claims cover the use of vafidemstat for treating aggression and social withdrawal, symptoms associated with various CNS disorders [2] - The Japanese patent will remain in force until at least 2038, with potential extensions, and corresponding patents have been granted in multiple countries including Europe, Australia, and Canada [3][4] - Oryzon holds additional patents for vafidemstat targeting CNS disorders, expected to remain valid until at least 2040, enhancing the company's intellectual property position [5] Clinical Development - Oryzon is preparing a Phase III trial for vafidemstat to evaluate its efficacy in treating aggression in borderline personality disorder (BPD) and has ongoing Phase II trials in autism spectrum disorder (ASD) and schizophrenia [2][8] - Vafidemstat has shown positive results in previous Phase IIa trials for aggression in psychiatric disorders and has demonstrated anti-inflammatory effects in severe Covid-19 patients [7][8] Company Overview - Founded in 2000, Oryzon Genomics is a clinical-stage biopharmaceutical company focused on epigenetics and personalized medicine in CNS disorders and oncology, with a strong clinical portfolio including two LSD1 inhibitors [6] - The company is advancing a precision medicine approach in CNS disorders, preparing trials for genetically defined patient subpopulations [8]